Voyager Therapeutics (STU:VT6) FCF Margin % : 290.15% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Voyager Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Voyager Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was €52.1 Mil. Voyager Therapeutics's Revenue for the three months ended in Mar. 2024 was €18.0 Mil. Therefore, Voyager Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 290.15%.

As of today, Voyager Therapeutics's current FCF Yield % is 1.87%.

The historical rank and industry rank for Voyager Therapeutics's FCF Margin % or its related term are showing as below:

STU:VT6' s FCF Margin % Range Over the Past 10 Years
Min: -644.65 Med: -63.59 Max: 232.31
Current: 6.65

During the past 11 years, the highest FCF Margin % of Voyager Therapeutics was 232.31%. The lowest was -644.65%. And the median was -63.59%.

STU:VT6's FCF Margin % is ranked better than
84.2% of 1038 companies
in the Biotechnology industry
Industry Median: -136.31 vs STU:VT6: 6.65

Voyager Therapeutics FCF Margin % Historical Data

The historical data trend for Voyager Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyager Therapeutics FCF Margin % Chart

Voyager Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

39.23

-63.59

-147.36

-36.67

29.86

Voyager Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															81.78	-42.15	-473.24	-27.22	290.15

Competitive Comparison of Voyager Therapeutics's FCF Margin %

For the Biotechnology subindustry, Voyager Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyager Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Voyager Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Voyager Therapeutics's FCF Margin % falls into.

Voyager Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Voyager Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	68.466	/	229.257
	=	29.86 %

Voyager Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	52.096	/	17.955
	=	290.15 %

Voyager Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Voyager Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyager Therapeutics (STU:VT6) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Voyager Therapeutics Inc (STU:VT6) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

VYGR:USA VT6:Germany

Address

64 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.voyagertherapeutics.com

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.

Voyager Therapeutics (STU:VT6) Headlines

No Headlines